SRRK Scholar Rock
- 9.450
- +0.020+0.21%
- 9.450
- 0.0000.00%
Scholar Rock News
Scholar Rock Holding Is Maintained at Outperform by BMO Capital
Scholar Rock Holding Is Maintained at Outperform by BMO Capital
BMO Capital Maintains Scholar Rock(SRRK.US) With Buy Rating, Raises Target Price to $31
BMO Capital analyst Etzer Darout maintains $Scholar Rock(SRRK.US)$ with a buy rating, and adjusts the target price from $29 to $31.According to TipRanks data, the analyst has a success rate of 58.7% a
Express News | Scholar Rock Holding Corp : BMO Raises Target Price to $31 From $29
BMO Capital Maintains Scholar Rock(SRRK.US) With Buy Rating, Maintains Target Price $29
BMO Capital analyst Etzer Darout maintains $Scholar Rock(SRRK.US)$ with a buy rating, and maintains the target price at $29.According to TipRanks data, the analyst has a success rate of 58.7% and a to
Truist Financial Maintains Scholar Rock(SRRK.US) With Buy Rating
Truist Financial analyst Srikripa Devarakonda maintains $Scholar Rock(SRRK.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 48.9% and a total average return of 5.5%
Scholar Rock Reports 'Encouraging' Phase 1 Trial Results in Advanced Solid Tumors
Scholar Rock (SRRK) late Monday reported "encouraging" data from a phase 1 proof-of-concept trial of SRK-181 in combination with pembrolizumab in patients with advanced solid tumors. The company said
12 Health Care Stocks Moving In Monday's After-Market Session
GainersFibroGen (NASDAQ:FGEN) stock moved upwards by 24.4% to $1.53 during Monday's after-market session. The market value of their outstanding shares is at $152.1 million. Candel Therapeutics (NASDAQ
Express News | Scholar Rock Holding Corp - Promising Objective Response Rates (Orr) Were Observed in Multiple Tumor Types in Anti-Pd-(L)1 Resistant Patients
Express News | Scholar Rock Holding Corp - Srk-181 Combination With Pembrolizumab Was Generally Well Tolerated
Express News | Scholar Rock Presents New Data From Srk-181 Phase 1 Dragon Trial at Asco 2024 Annual Meeting
Scholar Rock to Present New Data From SRK-181 Phase 1 DRAGON Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced it will present new data from its Phase 1 DRAGON proof-of-concept trial of SRK-181 in combination with pembrolizumab in patients with advanced solid tumors in an oral presentation during the American Society of Clinical Oncology (ASCO) Annual Meeting being held May 31 – June 4 in Chicago.
A Quick Look at Today's Ratings for Scholar Rock(SRRK.US), With a Forecast Between $28 to $30
On May 23, major Wall Street analysts update their ratings for $Scholar Rock(SRRK.US)$, with price targets ranging from $28 to $30.TD Cowen analyst Marc Frahm maintains with a buy rating.BMO Capital a
Analysts' Top Healthcare Picks: Scholar Rock Holding (SRRK), Gilead Sciences (GILD)
Scholar Rock Holding (SRRK) Receives a Buy From Truist Financial
Buy Rating Affirmed for Scholar Rock Holding on Strong Drug Pipeline and Market Readiness
Express News | Scholar Rock Initiates Phase 2 EMBRAZE Trial Of Apitegromab In Obesity And Announces New Preclinical Data Showing SRK-439 Is 'More Potent Than an Anti-ActRII Antibody in Maintaining Lean Mass in Diet-induced Obesity (DIO) Mice'
Express News | Scholar Rock Holding Corp - Primary Data From Embraze Will Inform Scholar Rock's Development of Srk-439 Towards an Anticipated Ind Filing in 2025
Express News | Scholar Rock Holding Corp - Primary Data From Embraze Are Expected in Mid-2025
Express News | Scholar Rock Announces Initiation of Phase 2 Embraze Trial of Apitegromab in Obesity and New Preclinical Data Supporting Srk-439 in Obesity
Scholar Rock to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic dis
Analysis
Price Target
No Data
